CS
HEPA

Credit Suisse’s Hepion Pharmaceuticals HEPA Stock Holding History

Credit Suisse’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$1K – 4134
2022
Q2 		$1K Buy
+2
New +$1.67K ﹤0.01% 3820
2019
Q2 		– Hold
0
– -$5K – 4162
2019
Q1 		– Hold
0
– – – 3958
2018
Q4 		– Hold
0
– – – 3853
2018
Q3 		– Hold
0
– – – 3754
2018
Q2 		– Hold
0
– – – 3917
2018
Q1 		– Hold
0
– – – 3909
2017
Q4 		– Hold
0
– – – 3904
2017
Q3 		– Hold
0
– – – 4120
2017
Q2 		– Hold
0
– – – 3732
2017
Q1 		– Hold
0
– – – 3556
2016
Q4 		– Hold
0
– – – 3832
2015
Q3 		– Hold
0
– -$61K – 4358
2015
Q2 		– Hold
0
– – – 4444

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Credit Suisse's HEPA Position: Q3 2022 in Review

Credit Suisse sold out of Hepion Pharmaceuticals (HEPA) in Q3 2022, closing a stake of 2 shares — an estimated $1K sold.

Credit Suisse first reported a position in HEPA in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 25 funds tracked by Wall St. Rank hold HEPA as of Q3 2022.

  • Credit Suisse reported no remaining Hepion Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 2 Hepion Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Credit Suisse first reported a position in Hepion Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Hepion Pharmaceuticals position peaked at $1K in Q2 2022.
  • 25 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.